Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C

@inproceedings{Veldt2007RandomizedPC,
  title={Randomized placebo controlled phase I/II trial of α-galactosylceramide for the treatment of chronic hepatitis C},
  author={Bart J. Veldt and Hans van der Vliet and Boudewina M. von Blomberg and Hans Van Vlierberghe and Guido G H Gerken and Nobusuke Nishi and Kunihiko Hayashi and Rik J. Scheper and Robert J. de Knegt and A.J.M. van den Eertwegh and Harry L. A. Janssen and Carin M.J. van Nieuwkerk},
  year={2007}
}
Background/Aims The glycosphingolipid α-galactosylceramide has been shown to activate invariant natural killer T cells when presented in the context of CD1d and induces powerful antiviral immune responses via the production of inflammatory cytokines. The aim of this study was to investigate the safety and the antiviral activity of α-galactosylceramide as a novel class of treatment for chronic hepatitis C patients. Methods International multicenter dose-escalating randomized placebo-controlled… CONTINUE READING

Similar Papers

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 12 CITATIONS

Immune-based therapy for chronic hepatitis C.

  • Journal of leukocyte biology
  • 2009
VIEW 1 EXCERPT
CITES BACKGROUND